Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm (Q40679730)

22 September 2017

title

Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm (English)

1 reference

22 September 2017

0 references

1

1 reference

22 September 2017

3

Eric Nuermberger

1 reference

22 September 2017

Jotam G Pasipanodya

2

1 reference

22 September 2017

Klaus Romero

series ordinal

4

1 reference

22 September 2017

Debra Hanna

series ordinal

5

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 August 2015

1 reference

Clinical Infectious Diseases

22 September 2017

published in

1 reference

22 September 2017

volume

61 Suppl 1

1 reference

22 September 2017

page(s)

S18-24

1 reference

Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Nonclinical models for antituberculosis drug development: a landscape analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Learning versus confirming in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

The Rapid Development of Fluoroquinolone Resistance inM. tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Fluoroquinolone Resistance in Patients with Newly Diagnosed Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV426

21 January 2018

Identifiers

DOI

10.1093/CID/CIV426

1 reference

22 September 2017

1 reference